KDR and gastric cancer: Apatinib, a novel oral small molecule tyrosine kinase inhibitor targeting VEGFR-2, has demonstrated good safety, tolerability, and efficacy in the treatment of patients with advanced metastatic GC based on phase I–III trials [7–9].